Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Ailani

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Headache|January 5, 2023
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraineAndrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache|February 21, 2022
Patient preference for early onset of efficacy of preventive migraine treatmentsJessica Ailani, Paul Winner, Ann Hartry, et al.
JAMA|June 15, 2021
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical TrialPaul K Winner, Peter McAllister, George Chakhava, et al.
Neurology. Clinical Practice|February 1, 2021
Sphenopalatine ganglion block in primary headaches: An American Headache Society member surveyJohn G Burkett, Matthew S Robbins, Carrie E Robertson, et al.
BMC Neurology|June 6, 2022
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
Headache|April 1, 2020
Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to InsurersChristina L Szperka, Jessica Ailani, Rebecca Barmherzig, et al.
BMC Neurology|September 6, 2023
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
European Journal of Neurology|November 13, 2023
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trialMessoud Ashina, Richard B Lipton, Jessica Ailani, et al.
European Journal of Neurology|March 16, 2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have FailedJessica Ailani, Messoud Ashina, Susanne F Awad, et al.
Clinical Drug Investigation|January 18, 2022
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Headache|January 5, 2023
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraineAndrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache|February 21, 2022
Patient preference for early onset of efficacy of preventive migraine treatmentsJessica Ailani, Paul Winner, Ann Hartry, et al.
JAMA|June 15, 2021
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical TrialPaul K Winner, Peter McAllister, George Chakhava, et al.
Neurology. Clinical Practice|February 1, 2021
Sphenopalatine ganglion block in primary headaches: An American Headache Society member surveyJohn G Burkett, Matthew S Robbins, Carrie E Robertson, et al.
BMC Neurology|June 6, 2022
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
Headache|April 1, 2020
Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to InsurersChristina L Szperka, Jessica Ailani, Rebecca Barmherzig, et al.
BMC Neurology|September 6, 2023
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
European Journal of Neurology|November 13, 2023
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trialMessoud Ashina, Richard B Lipton, Jessica Ailani, et al.
European Journal of Neurology|March 16, 2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have FailedJessica Ailani, Messoud Ashina, Susanne F Awad, et al.
Clinical Drug Investigation|January 18, 2022
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Pageof 12